Preferred Label : dulaglutide;

MeSH note : GLP-1 immunoglobulin G (IgG4) Fc fusion protein with extended activity; a hypoglycemic agent;

MeSH hyponym : LY-2189265; LY2189265;

Is substance : O;

UNII : WTT295HSY5;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3282758/fr/trulicity-dulaglutide
2021
false
false
false
France
evaluation of the transparency committee
dulaglutide
Trulicity
dulaglutide

---
https://www.has-sante.fr/jcms/p_3225392/fr/trulicity
2020
false
false
false
France
treatment outcome
insurance, health, reimbursement
diabetes mellitus, type 2
injections, subcutaneous
hypoglycemic agents
adult
drug therapy, combination
Product containing only dulaglutide (medicinal product)
evaluation of the transparency committee
dulaglutide
immunoglobulin fc fragments
recombinant fusion proteins
glucagon-like peptides
immunoglobulin fc fragments
recombinant fusion proteins

---
https://www.usherbrooke.ca/baladocritique/archives/episode-26-etude-rewind/
2019
false
false
false
false
Canada
immunoglobulin fc fragments
glucagon-like peptides
recombinant fusion proteins
cardiovascular diseases
treatment outcome
hypoglycemic agents
Glucagon-Like Peptide-1 Receptor
sound
diabetes mellitus, type 2
dulaglutide

---
Summary Basis of Decision (SBD) for Trulicity
Dulaglutide, 0.75 mg/0.5 mL and 1.5 mg/0.5 mL, solution, subcutaneous injection
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00244
2016
false
false
false
Canada
French
English
treatment outcome
summary of product characteristics
immunoglobulin fc fragments
recombinant fusion proteins
drug approval
hypoglycemic agents
hypoglycemic agents
glucagon-like peptides
adult
diabetes mellitus, type 2
drug therapy, combination
injections, subcutaneous
aged
Glycated Hemoglobin
drug evaluation, preclinical
canada
metformin
sulfonylurea compounds
insulin
Glucagon-Like Peptide-1 Receptor
dulaglutide
immunoglobulin fc fragments
recombinant fusion proteins
dulaglutide
dulaglutide

---
http://www.riziv.fgov.be/SiteCollectionDocuments/consensus_litterature_resume_20161117.pdf
2016
false
false
false
Belgium
French
GLP-1 Mimetics
diabetes mellitus, type 2
review of literature
consensus
GLP-1 Mimetics
treatment outcome
albiglutide
albiglutide
Glucagon-like peptide-1 (GLP-1) analogues
drug therapy, combination
metformin
hypoglycemic agents
hypoglycemic agents
glimepiride
dulaglutide
dulaglutide
Liraglutide
Liraglutide
Sitagliptin Phosphate
sulfonylurea compounds
comparative effectiveness research
arterial pressure
insulin
thyroid neoplasms
pancreatitis
Injection Site Reaction
cardiovascular diseases
practice guidelines as topic
Evidence-Based medicine
rGLP-1 protein
rGLP-1 protein
glucagon-like peptide 1
glucagon-like peptide 1
glucagon-like peptide 1
immunoglobulin fc fragments
recombinant fusion proteins
glucagon-like peptides
glucagon-like peptides
immunoglobulin fc fragments
recombinant fusion proteins
glucagon-like peptides
peptides
venoms
peptides
venoms
thiazolidinediones
Pioglitazone
Exenatide
Exenatide

---
https://www.ema.europa.eu/medicines/human/EPAR/Trulicity
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
immunoglobulin fc fragments
recombinant fusion proteins
drug approval
europe
hypoglycemic agents
hypoglycemic agents
glucagon-like peptides
adult
diabetes mellitus, type 2
drug therapy, combination
injections, subcutaneous
Pre-filled Pen Syringe
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
Glycated Hemoglobin
drug evaluation, preclinical
Prefilled Syringe Dosage Form
Glucagon-Like Peptide-1 Receptor
dulaglutide
immunoglobulin fc fragments
recombinant fusion proteins
dulaglutide
dulaglutide

---
http://www.has-sante.fr/portail/jcms/c_2036398/fr/trulicity
http://www.has-sante.fr/portail/jcms/c_2036398/fr/trulicity-dulaglutide-antidiabetique
2015
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
insurance, health, reimbursement
treatment outcome
drug therapy, combination
insulins
dulaglutide
dulaglutide
hypoglycemic agents
hypoglycemic agents
glucagon-like peptide 1
diabetes mellitus, type 2
metformin
adult
injections, subcutaneous
dulaglutide
dulaglutide
dulaglutide
immunoglobulin fc fragments
recombinant fusion proteins
glucagon-like peptides
glucagon-like peptides
immunoglobulin fc fragments
recombinant fusion proteins
glucagon-like peptides

---
Nous contacter.
14/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.